SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Social media platforms are seeing a surge in speculative chatter as investors debate the legitimacy of tokenized pre-IPO assets, with many users warning of potential scams while others track news regarding a long-rumored SpaceX public offering. Community members are actively analyzing the aerospace sector, focusing on the potential impact of a high-profile IPO and debating whether current market excitement reflects genuine valuation or a bubble driven by retail FOMO.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin (BNKR) is attracting significant attention as investors speculate on its role in the AI-agent infrastructure space, with the community actively discussing potential institutional interest and long-term utility. Despite recent price volatility, supporters are highlighting bullish ecosystem developments and active development as reasons to maintain a long-term position.

Swell

The community is actively debating the potential of Swell, with supporters highlighting its liquid staking utility, institutional backing, and low market cap as key drivers for long-term growth. Conversely, critics frequently dismiss the asset as a speculative project, pointing to recurring price volatility and concerns over supply issuance as reasons for caution.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. (EMAT) is gaining momentum as investors weigh its potential as a vertically integrated domestic rare earth magnet manufacturer against concerns regarding its micro-float and high insider ownership. Community discussion is split between excitement over the stock's positioning as a strategic alternative to foreign supply chains and caution regarding its characteristic high volatility and potential for sharp price swings.

DEGEN is a reward token for Farcaster users, born from meme culture. It features a unique tipping system that allows the community to reward high-quality content creators. DEGEN also powers the Degen Chain, one of the pioneering Layer 3s launched on Base. Known as the “Las Vegas of blockchains,” it provides a platform for building and using Degen apps, offering a space for fun, innovation, and community-driven experiences.

League of Degens 

The community is actively discussing $DEGEN, pointing to a mix of optimism surrounding potential exchange listings and a new beta app while others express frustration over token performance. Investors remain hyper-focused on upcoming project catalysts and social media branding as they debate whether the token is currently at a critical accumulation phase.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following an exclusive U.S. supply agreement for the Tokyo strain of BCG to address the ongoing domestic shortage, a move the community views as a strategic breakthrough that strengthens the company's competitive position against major pharmaceutical players. Investors are actively discussing the potential for accelerated regulatory pathways, the synergy between this supply and Anktiva, and the anticipation of further catalysts being revealed at the upcoming American Urological Association conference.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is trending as investors monitor Q4 earnings results and weigh the ongoing growth of immunology blockbusters Skyrizi and Rinvoq against the managed decline of Humira revenues. Meanwhile, community discussions are heavily focused on the company's potential M&A appetite in the obesity and oncology sectors, with retail sentiment remaining vigilant regarding potential competitive threats and pipeline expansion strategies.

WW International, Inc. engages in the provision of weight management services. It operates through the following geographical segments: United States, Germany, and Other. The company was founded by Jean Nidetch in 1963 and is headquartered in New York, NY.

WW International Inc - Ordinary Shares - New

WW International, Inc. Common Stock

WW International is gaining traction as investors speculate on a turnaround driven by strategic partnerships with GLP-1 medication providers and debt-reduction efforts. The community remains divided, with some betting on a successful pivot toward clinical weight-loss solutions while others remain skeptical due to the company's historical financial struggles and competitive pressure.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is experiencing a surge in investor interest driven by strong prescription growth, successful patent protection, and a clear path toward operating profitability in the coming quarters. The community is actively discussing the stock's potential for acquisition by larger pharmaceutical firms, while closely monitoring the ongoing battle against high short interest and institutional accumulation patterns.

The Render Network is a leading decentralized GPU compute platform for applications ranging from 3D rendering to machine learning and generative AI.  The network connects node operators looking to monetize their idle GPU compute power with artists and developers looking to scale intensive 3D rendering work and machine learning applications in the cloud. Through a decentralized peer-to-peer network, the Render Network achieves unprecedented levels of scale, speed, and economic efficiency. Facilitated by the Render Network Foundation, the ecosystem empowers artists and developers to build services and applications for the emerging digital economy.

Render Token (SOL)

Render Token is currently capturing significant attention as investors double down on decentralized AI infrastructure and GPU-based compute plays. The community is heavily focused on the protocol's utility in the expanding AI landscape, with many traders actively accumulating positions while discussing its long-term potential compared to other artificial intelligence and DePIN projects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Stifel lowered the firm's price target on DraftKings to $44 from $46.</li><li>Guggenheim has also lowered the firm's price target on DraftKings to $42 from $45.</li><li>JPMorgan said that Gaming stocks "are carrying a lot of baggage and negativity," so investors should be selective.&nbsp;</li></ul>Shares of DraftKings (<a href="https://stocktwits.com/symbol/DKNG">DKNG</a>) fell more than 6% on Friday after several analysts slashed their price targets on the stock ahead of its expected fourth quarter (Q4) earnings results on Monday.&nbsp;<h2 class="st-heading-2">Price Cuts</h2>Stifel lowered the firm's price target on DraftKings to $44 from $46 and kept a ‘Buy’ rating on the shares.The firm said it has approached Q4 earnings for the online gambling group cautiously despite mostly attractive valuations, noting that it tactically favors DraftKings in the near-term given NBA handle share momentum, de-risked consensus FY26 (fiscal year 2026) estimates, potential upside from the Winter Olympics and World Cup.&nbsp;Guggenheim also lowered the firm's price target on DraftKings to $42 from $45 and kept a ‘Buy’ rating on the shares after updating the firm's model for Q4 and "an initially more conservative" 2026 outlook.&nbsp;Given recent guidance challenges, it would be prudent for DraftKings to start 2026 in "a very reasonable zone and hopefully exceed expectations throughout the year," the analyst said in a note.&nbsp;JPMorgan last week also lowered the firm's price target on DraftKings to $41 from $42 and kept an ‘Overweight’ rating on the shares.&nbsp;Gaming stocks "are carrying a lot of baggage and negativity," so investors should be selective, the analyst said.&nbsp;<h2 class="st-heading-2">Upcoming Q4 Earnings</h2>Draftkings is expected to post a revenue of $1.97 billion in Q4, according to data from fiscal.ai.&nbsp;It had missed analyst estimates for third quarter revenue.&nbsp;The company is also expected to report a &nbsp;profit of $0.12 per share in the quarter. It posted a loss of $0.28 per share in the corresponding quarter of 2024.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around DKNG trended in ‘neutral’ territory amid ‘high’ message volume.&nbsp;One user said that the gaming segment “is filled with too much risk from all angles.”&nbsp;“And it’s a low margin business to be home with. Risk reward is not in the bulls camp,” they added.<stembedurl>https://stocktwits.com/Balls_deeper/message/643458827</stembedurl>One bullish user said that they are adding more of Draftkings stock amid the selloff.<stembedurl>https://stocktwits.com/howyee1234/message/643455001</stembedurl>Shares in the company have fallen 34% over the past 12 months.&nbsp; &nbsp;

In this photo illustration, the logo of DraftKings Inc. is displayed on a smartphone screen. 

DraftKings Shares Are Falling Today – Here’s Why

Analysts from Stifel, JPMorgan and Guggenheim have slashed their price target on Draftkings ahead of its Q4 earnings due Monday.

GGUSD
Good Game US Dollar

Chart

News

Sentiment

Info

Historical Prices

Compact View

Poll

Latest GGUSD News

GGUSDGood Game US Dollar